Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cross-reactivity00:42

Cross-reactivity

33.8K
Overview
33.8K
Vaccinations01:51

Vaccinations

53.6K
Overview
53.6K
Vaccines01:21

Vaccines

41
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
41
Humoral Immune Responses01:36

Humoral Immune Responses

86.0K
Overview
86.0K
Vaccine Production01:23

Vaccine Production

57
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
57

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Integrated Surveillance Strategies and Clinical Characteristics of Arboviral Diseases in a Pediatric Cohort in Merida, Mexico, 2021-2023.

The American journal of tropical medicine and hygiene·2026
Same author

Improving Assessment of Vaccine Effectiveness by Coupling Test-negative Design Studies with Survival Models.

Epidemiology (Cambridge, Mass.)·2026
Same author

Improving Assessment of Vaccine Effectiveness by Coupling Test-Negative Design Studies with Survival Models.

medRxiv : the preprint server for health sciences·2025
Same author

Acute SARS-CoV-2 infection.

Nature reviews. Disease primers·2025
Same author

Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.

The New England journal of medicine·2025
Same author

Estimating transmissibility of Zika virus in Colombia in the presence of surveillance bias.

Nature communications·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Mar 27, 2026

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses
05:22

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

Published on: November 4, 2025

795

エボラ予防接種 - 著者の回答

Ira M Longini1, Matthias Egger2, Natalie E Dean1

  • 1Department of Biostatistics, University of Florida, Gainesville, FL, USA.

Lancet (London, England)
|January 8, 2016
PubMed
まとめ

No abstract available in PubMed .

さらに関連する動画

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.7K

関連する実験動画

Last Updated: Mar 27, 2026

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses
05:22

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

Published on: November 4, 2025

795
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.7K